Efficacy of Shoushen granule on adenosine triphosphate binding cassette transporter A1, proprotein convertase subtilisin/kexin type 9 and toll-like receptor 4/nuclear factor kappa-B signaling pathway in ApoE-knockout mice

OBJECTIVE: To evaluate the efficacy of Shoushen granule, prepared with four Chinese medicinals, on the targeted regulation of adenosine triphosphate binding cassette transporter A1 (ABCA1) through proprotein convertase subtilisin/kexin type 9 (PCSK9) and toll-like receptor 4 (TLR4)/nuclear factor kappa-B (NF-kappa B) signaling pathway to affect atherosclerosis (AS) in ApoE-knockout (ApoE(-/-)) mice. METHODS: ApoE(-/-) mice fed with a high-fat diet were used for AS modeling and divided into Model, Shoushen, and Atorvastatin groups. C57BL/6J mice at the same age and background strain were included in the Control group. Western blot and immunohistochemistry were used to measure ABCA1, PCSK9, TLR4, and NE-kappa B protein expression in mouse aortas. Enzyme-linked immuno sorbent assay was used to measure mouse serum tumor necrosis factor -alpha (TNF-alpha), interleukin-10 (IL-10), monocyte chemoattractant protein 1 (MCP-1), and intercellular cell adhesion molecule-1 (ICAM-1) expression. Serum lipid profiles and histopathology were also assessed. Shoushen granule were composed of Heshouwu (Radix Polygoni Multiflori) 15 g, Gouqizi (Fructus Lycii) 15 g, Sheng shanzha (Raw Fructus Crataegus Pinnatifidae) 10 g, and Sanqi (Radix Notoginseng) 3 g. RESULTS: ApoE(-/-) mice fed with a high-fat diet had notable AS lesions, with reduced ABCA1 and IL-10 levels, elevated PCSK9, TLR4, NE-kappa B, TNF-alpha, MCP-1, and ICAM-1 expression, and increased total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) contents. With drug interventions, the areas of AS plaques were significantly reduced, the ABCA1 and IL-10 levels were increase, while the PCSK9, TLR4, NF-kappa B, TC, and LDL-C contents, and the TNF-alpha, MCP-1, and ICAM-1 expression were reduced. CONCLUSION: Shoushen granule effectively interfered with AS development by antagonizing the expression of key factors of the PCSK9 and TLR4/NF-kappa B signaling pathway to upregulate ABCA1 expression. (C) 2019 JTCM. All rights reserved.